More

• UPDATE 1-Actavis to buy Warner Chilcott in $8.5 billion stock deal Monday, 20 May 2013 | 7:49 AM ET

  May 20- Generic drugmaker Actavis Inc, which has been the subject of intense takeover speculation, said on Monday that it had struck a deal to buy specialty pharmaceuticals company Warner Chilcott Plc for $8.5 billion in stock.

• Early Movers: DE, BA, GOOG, GPS & More Wednesday, 15 May 2013 | 7:42 AM ET

  

  Some of the names on the move ahead of the open.

• UPDATE 2-Valeant raises profit forecast, hunts for deals Thursday, 2 May 2013 | 9:21 AM ET

  *Sees 2013 cash EPS $5.55- $5.85 vs prior fcast $5.45- $5.75. The fast-growing drugmaker said it now expected an adjusted 2013 profit, which it calls cash earnings, of between $5.55 and $5.85 per share, up from its previous forecast of $5.45 to $5.75.

• UPDATE 1-U.S. FDA's Deborah Autor to join drugmaker Mylan Tuesday, 30 Apr 2013 | 4:21 PM ET

  April 30- Generic drugmaker Mylan Inc said on Tuesday it hired Deborah Autor, deputy commissioner for global regulatory operations and policy at the U.S. Food and Drug Administration, to help oversee its global regulatory strategy.

• UPDATE 1-U.S. FDA approves Raptor's drug for nephropathic cystinosis Tuesday, 30 Apr 2013 | 1:02 PM ET

  *FDA approves Procysbi for rare genetic disorder. WASHINGTON, April 30- The U.S. Food and Drug Administration has approved an experimental drug from Raptor Pharmaceutical Corp to treat a rare genetic disorder that can cause irreversible tissue damage, organ failure and premature death.

• Fed May Provide a Safety Net for the Market Friday, 26 Apr 2013 | 8:08 PM ET

  

  The Fed is expected to repeat its dovish message in the coming week, which could provide a safety net for the market amid a big wave of earnings and the April jobs report.

• Final Trade: Your First Move for Tuesday, March 26 Monday, 25 Mar 2013 | 6:47 PM ET

  

  The "Fast Money" traders share their final trades of the day.

• Pfizer gets Celebrex patent extension, sues generic companies Tuesday, 5 Mar 2013 | 11:01 AM ET

  March 5- U.S. regulators granted Pfizer Inc a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December 2015, the company said on Tuesday.

• US STOCKS-Wall St ends flat after late fade; S&P up for 4th month Thursday, 28 Feb 2013 | 4:42 PM ET

  *J.C. Penney, Groupon both sink on weak revenue. NEW YORK, Feb 28- U.S. stocks ended flat on Thursday, giving up modest gains late in the session, denying the Dow a chance to inch closer to all-time highs. JC Penney Co Inc was the day's biggest loser, falling 17 percent to $17.57 after the department store operator reported a steep drop in sales.

• CORRECTED-US STOCKS-Wall Street edges up; Dow and S&P near records Thursday, 28 Feb 2013 | 3:52 PM ET

  *J.C. Penney, Groupon both sink on weak revenue. NEW YORK, Feb 28- U.S. stocks rose modestly on low volume on Thursday after strong economic data, but the proximity of record highs for the Dow and the S&P 500 gave investors a reason to keep gains in check.

• US STOCKS-Wall Street edges higher, Dow and S&P records a hurdle Thursday, 28 Feb 2013 | 2:11 PM ET

  *J.C. Penney, Groupon both sink on weak revenue. NEW YORK, Feb 28- U.S. stocks rose modestly on low volume on Thursday after strong economic data, but the proximity of record highs for the Dow and the S&P 500 gave investors a reason to keep gains in check.

• US STOCKS-Wall St drifts after two-day run, Dow record in sight Thursday, 28 Feb 2013 | 11:43 AM ET

  *J.C. Penney, Groupon both sink on weak revenue. NEW YORK, Feb 28- U.S. stocks edged higher on Thursday with investors hard-pressed to lift indexes to multi-year highs despite strong economic data.

• US STOCKS-Wall Street advances, on track for third day of gains Thursday, 28 Feb 2013 | 10:03 AM ET

  *J.C. Penney, Groupon both sink on weak revenue. NEW YORK, Feb 28- U.S. stocks edged higher on Thursday, pointing to a third straight day of gains in the wake of some strong economic data, though a further advance may be limited with major averages near multi-year highs.

• Mylan CEO on Earnings Beat  Thursday, 28 Feb 2013 | 12:00 AM ET

  

  Mylan's aquisition of Agila is expected to double its business. Heather Bresch, Myland CEO, offers insight.

• UPDATE 1-Mylan to buy injectable drugs unit of India's Strides for $1.6 bln Wednesday, 27 Feb 2013 | 6:18 PM ET

  Feb 27- Generic drugmaker Mylan Inc said it would buy the injectable drugs unit of India's Strides Arcolab Ltd for $1.6 billion to expand its presence in the fast-growing generic injectables market.

• UPDATE 1-Appeals court upholds patent on Merck's Vytorin Thursday, 7 Feb 2013 | 1:51 PM ET

  WASHINGTON, Feb 7- The patent on Merck& Co's cholesterol fighters Zetia and Vytorin, two of the drugmaker's biggest products, is valid, a U.S. appeals court ruled on Thursday. The U.S. Court of Appeals for the Federal Circuit did not discuss the ruling at length and simply affirmed a decision by a lower court in New Jersey.